secwatch / observer
8-K filed June 1, 2026, 8:55 AM ET ticker LIXT CIK 0001335105
other material confidence high sentiment positive materiality 0.85

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

item 5.02item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001493152-26-026544
form_type
8-K
ticker
LIXT
cik
0001335105
company_name
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
filed_at
2026-06-01T12:55:34+00:00
discovered_at
2026-06-01T13:00:00.524467+00:00
generated_at
2026-06-01T13:00:26.464320+00:00
sec_items
["5.02", "7.01", "9.01"]
event_type
other_material
sentiment
positive
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001493152-26-026544
json_url
https://secwatch.observer/filing/0001493152-26-026544.json
markdown_url
https://secwatch.observer/filing/0001493152-26-026544.md
text_url
https://secwatch.observer/filing/0001493152-26-026544.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stuart D. Porter

Director
LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Effective
2026-05-29
Filed
June 1, 2026, 8:55 AM ET
On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Source-grounded claims

8f181a2c8a

Stuart D. Porter was appointed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

ELOX

Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors

Eloxx Pharmaceuticals, Inc. June 1, 2026, 7:00 AM ET other_material Items 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board

Filing page SEC filing

FDXF

FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed

FedEx Freight Holding Company, Inc. June 1, 2026, 6:46 AM ET other_material Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board

Filing page SEC filing

FXAC

FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross

FortuneX Acquisition Corp May 29, 2026, 5:32 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.

Filing page SEC filing

OHAC

Oceanhawk Acquisition Corp. closes upsized $160M IPO of 16M units at $10/unit

Oceanhawk Acquisition Corp. May 27, 2026, 4:01 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

On May 20, 2026, in connection with the IPO, each of Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury and Jonathan Nickell (collectively, the “ Directors ”) was appointed to the board of directors of the Company (the “ Board ”).

Filing page SEC filing

LCLN

Lincoln International completes IPO of 24.2M shares at $20.00, raising $473.7M in gross proceeds

Lincoln International, Inc. May 26, 2026, 5:19 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

Effective May 19, 2026, Ms. M. Christie Smith and Mr. John W. Oleniczak were appointed to the board of directors of the Company.

Filing page SEC filing

ENS

EnerSys realigns to three segments, names presidents for NIS, IMS, PPS

EnerSys May 28, 2026, 4:15 PM ET other_material Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: other_material

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

As a result of the Company's Segment Realignment there will be a change in executive titles as follows: • Keith D. Fisher – President, Network & Infrastructure Solutions • Chad C. Uplinger – President, Industrial Mobility Solutions • Mark E. Matthews – Chief Technology Officer and President, Precision Power Solutions

Filing page SEC filing

CRMT

America's Car-Mart forms special committee for strategic alternatives; appoints new independent director

AMERICAS CARMART INC May 29, 2026, 5:30 PM ET other_material Items 1.01, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.

Filing page SEC filing

SYRE

Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns

Spyre Therapeutics, Inc. May 29, 2026, 4:45 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material

This filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Comparable filing

In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.

Filing page SEC filing

Source: SEC EDGAR
accession 0001493152-26-026544
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.